Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: A randomized, double-blind, multicenter study

Journal of the American Society of Nephrology

Volumn 16, Issue 3, 2005, Pages 800-807

  Lindberg, Jill S ^a,j   Culleton, Bruce ^b   Wong, Gordon ^c   Borah, Michael F ^d   Clark, Roderick V ^e   Shapiro, Warren B ^f   Roger, Simon D ^g   Husserl, Fred E ^a   Klassen, Preston S ^h   Guo, Matthew D ^h   Albizem, Moetaz B ^h   Coburn, Jack W ⁱ  

^a OCHSNER CLINIC FOUNDATION   (United States)

^b FOOTHILLS HOSPITAL   (Canada)

^c CREDIT VALLEY HOSPITAL   (Canada)

^d CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^e Our Lady of Lourdes Medical Center   (United States)

^f Brookdale Plaza Nephrology Associates   (United States)

^g GOSFORD HOSPITAL   (Australia)

^h AMGEN INC   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j New Orleans Nephrology Associates   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CALCIMIMETIC AGENT; CALCIUM; CINACALCET; PARATHYROID HORMONE; PHOSPHORUS; PLACEBO; NAPHTHALENE DERIVATIVE; VITAMIN D;

ADULT; ARTICLE; ASTHENIA; CALCIUM BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL DISEASE; HEADACHE; HEMODIALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA AND VOMITING; PERITONEAL DIALYSIS; PHASE 3 CLINICAL TRIAL; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SECONDARY HYPERPARATHYROIDISM; UPPER RESPIRATORY TRACT INFECTION; BLOOD; CHRONIC KIDNEY FAILURE; DRUG COMBINATION; MIDDLE AGED; ORAL DRUG ADMINISTRATION; RENAL REPLACEMENT THERAPY;

ADMINISTRATION, ORAL; ADULT; CALCIUM; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERPARATHYROIDISM, SECONDARY; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; NAPHTHALENES; PARATHYROID HORMONE; PERITONEAL DIALYSIS; PHOSPHORUS; RENAL DIALYSIS; VITAMIN D;

EID: 20544460709     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1681/ASN.2004060512     Document Type: Article

References (28)

1. Salem M: Hyperparathyroidism in the hemodialysis population: A survey of 612 patients. Am J Kidney Dis 29: 862-865, 1997
2. Billa V, Zhong A, Bargman J, Vas S, Wong PY, Oreopoulos DG: High prevalence of hyperparathyroidism among peritoneal dialysis patients: A review of 176 patients. Pent Dial Int 20: 315-321, 2000
3. Andress DL, Norris KC, Coburn JW, Slatopolsky EA, Sherrard DJ: Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure. N Engl J Med 321: 274-279, 1989
4. 2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. J Am Soc Nephrol 9: 1427-1432, 1998
5. 2) in dialysis patients with secondary hyperparathyroidism: A sequential comparison. Am J Kidney Dis 37: 532-543, 2001
6. Johnson CA, McCarthy J, Bailie GR, Deane J, Smith S: Analysis of renal bone disease treatment in dialysis patients. Am J Kidney Dis 39: 1270-1277, 2002
7. Indridason OS, Quarles LD: Comparison of treatments for mild secondary hyperparathyroidism in hemodialysis patients. Durham Renal Osteodystrophy Study Group. Kidney Int 57: 282-292, 2000
8. Ribeiro S, Ramos A, Brandao A, Rebelo JR, Guerra A, Resina C, Vila-Lobos A, Carvalho F, Remedio F, Ribeiro F: Cardiac valve calcification in haemodialysis patients: Role of calcium-phosphate metabolism. Nephrol Dial Transplant 13: 2037-2040, 1998
9. Block GA, Hulbert-Shearon TE, Levin NW, Port FK: Association of serum phosphorus and calcium X phosphate product with mortality risk in chronic hemodialysis patients: A national study. Am J Kidney Dis 31: 607-617, 1998
10. Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB: Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 342: 1478-1483, 2000
11. 4 product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 12: 2131-2138, 2001
12. National Kidney Foundation: K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42: S1-S202, 2003
13. Kim J, Pisoni RL, Danese MD, Satayathum S, Klassen P, Young EW: Achievement of proposed NKF-K/DOQI bone metabolism and disease guidelines: Results from the dialysis outcomes and practice patterns study (DOPPS) [Abstract]. J Am Soc Nephrol 13: 270A, 2003
14. Sherrard DJ, Hercz G, Pel Y, Maloney NA, Greenwood C, Manuel A, Saiphoo C, Fenton SS, Segre GV: The spectrum of bone disease in end-stage renal failure-An evolving disorder. Kidney Int 43: 436-442, 1993
15. Brown EM, Gamba G, Riccardi D, Lombardi M, Butters R, Kifor O, Sun A, Hediger MA, Lytton J, Hebert SC: Cloning and characterization of an extracellular Ca(2+)-sensing receptor from bovine parathyroid. Nature 366: 575-580, 1993
16. Nemeth EF, Steffey ME, Hammerland LG, Hung BC, Van Wagenen BC, DelMar EG, Balandrin MF: Calcimimetics with potent and selective activity on the parathyroid calcium receptor. Proc Natl Acad Sci U S A 95:4040-4045, 1998
17. Nemeth EF, Heaton WH, Miller M, Fox J, Balandrin MF, Van Wagenen BC, Colloton M, Karbon W, Scherrer J, Shatzen E, Rishton G, Scully S, Qi M, Harris R, Lacey D, Martin D: Pharmacodynamics of the type II calcimimetic compound cinacalcet HCl. J Pharmacol Exp Ther 308: 627-635, 2004
18. Hammerland LG, Garrett JE, Hung BC, Levinthal C, Nemeth EF: Allosteric activation of the Ca2+ receptor expressed in Xenopus laevis oocytes by NPS 467 or NPS 568. Mol Pharmacol 53: 1083-1088, 1998
19. Goodman WG, Hladik GA, Turner SA, Blaisdell PW, Goodkin DA, Liu W, Barri YM, Cohen RM, Coburn JW: The Calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. J Am Soc Nephrol 13: 1017-1024, 2002
20. Lindberg JS, Moe SM, Goodman WG, Coburn JW, Sprague SM, Liu W, Blaisdell PW, Brenner RM, Turner SA, Martin KJ: The calcimimetic AMG 073 reduces parathyroid hormone and calcium X phosphorus in secondary hyperparathyroidism. Kidney Int 63: 248-254, 2003
21. Quarles LD, Sherrard DJ, Adler S, Rosansky SJ, McCary LC, Liu W, Turner SA, Bushinsky DA: The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. J Am Soc Nephrol 14: 575-583, 2003
22. Block GA, Martin KJ, de Francisco ALM, Turner SA, Avram MM, Suranyi MG, Hercz G, Cunningham J, Abu-Alfa AK, Messa P, Coyne DW, Locatelli F, Cohen RM, Evenepoel P, Moe SM, Fournier A, Braun J, McCary LC, Zani VJ, Olson KA, Drueke TB, Goodman WG: Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 350: 1516-1525, 2004
23. Nussbaum SR, Zahradnik RJ, Lavigne JR, Brennan GL, Nozawa-Ung K, Kim LY, Keutmann HT, Wang CA, Potts JT Jr, Segre GV: Highly sensitive two-site immunoradiometric assay of parathyrin, and its clinical utility in evaluating patients with hypercalcemia. Clin Chem 33: 1364-1367, 1987
24. Kuritz SJ, Landis JR, Koch GG: A general overview of Mantel-Haenszel methods: Applications and recent developments. Annu Rev Public Health 9: 123-160, 1988
25. Goodman WG: Recent developments in the management of secondary hyperparathyroidism. Kidney Int 59: 1187-1201, 2001
26. Locatelli F, Cannata-Andia J, Drueke T, Horl W, Fouque D, Heimburger O, Ritz E: Management of disturbances of calcium and phosphate metabolism in chronic renal insufficiency, with emphasis on the control of hyperphosphataemia. Nephrol Dial Transplant 17: 723-731, 2002
27. Raggi P, Boulay A, Chasan-Taber S, Amin N, Dillon M, Burke SK, Chertow GM: Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease? J Am Coll Cardial 39: 695-701, 2002
28. Rayner HC, Pisoni RL, Bommer J, Canaud B, Recking E, Locatelli F, Piera L, Bragg-Gresham JL, Feldman HI, Goodkin DA, Gillespie B, Wolfe RA, Held PJ, Port FK: Mortality and hospitalization in haemodialysis patients in five European countries: Results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 19: 108-120, 2004